Cannabis Rescheduling Is Here. What It Means for Business Valuations.
On April 22, 2026, the Acting Attorney General issued a final order reclassifying FDA-approved marijuana products and state-licensed medical marijuana from Schedule I to Schedule III under the Controlled Substances Act. A formal DEA hearing on broader cannabis rescheduling is scheduled to begin June 29, 2026. This is the most consequential shift in federal marijuana […]
409A Valuations: Strategic Considerations for Private Company Equity Compensation
The Growing Importance of Equity Compensation Discipline For many private companies, 409A valuations are treated as a compliance requirement, completed to support option grants and satisfy regulatory expectations. However, when the process is approached as a periodic checkbox rather than a strategic input, it can introduce avoidable friction across the organization. Misalignment between grant timing […]
Portfolio Valuation Under ASC 820: A Practical Framework for Fund Managers
Valuing Carried Interest for Trust and Estate Planning: A Strategic Overview
Few assets present as many valuation challenges in the context of estate and gift planning as carried interest. The value of carried interest is contingent on future fund performance, is governed by complex waterfall mechanics, and is usually very illiquid. These characteristics make it both difficult to value and, in some cases, difficult to defend under IRS […]
2025 IPEV Valuation Guidelines: Key Principles and Practical Implications for Fund Managers
